JP2013529178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529178A5 JP2013529178A5 JP2012557275A JP2012557275A JP2013529178A5 JP 2013529178 A5 JP2013529178 A5 JP 2013529178A5 JP 2012557275 A JP2012557275 A JP 2012557275A JP 2012557275 A JP2012557275 A JP 2012557275A JP 2013529178 A5 JP2013529178 A5 JP 2013529178A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- protein
- fusion protein
- polynucleotide encoding
- antagonist peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31298210P | 2010-03-11 | 2010-03-11 | |
| US61/312,982 | 2010-03-11 | ||
| PCT/US2011/028070 WO2011112915A2 (en) | 2010-03-11 | 2011-03-11 | Methods and compositions containing fc fusiong proteins for enhancing immune responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529178A JP2013529178A (ja) | 2013-07-18 |
| JP2013529178A5 true JP2013529178A5 (cg-RX-API-DMAC7.html) | 2014-05-01 |
| JP5975886B2 JP5975886B2 (ja) | 2016-08-23 |
Family
ID=44564143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557275A Active JP5975886B2 (ja) | 2010-03-11 | 2011-03-11 | Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9296803B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2545174B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5975886B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102884194B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011112915A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2742251T3 (es) | 2009-03-16 | 2020-02-13 | Pangu Biopharma Ltd | Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas |
| CN105378075B (zh) | 2013-03-15 | 2022-04-05 | Atyr 医药公司 | 组氨酰-trna合成酶-fc缀合物 |
| EP3548070A4 (en) * | 2016-11-29 | 2020-07-22 | Health Research, Inc. | METHODS AND COMPOSITIONS FOR ANTI-CANCER THERAPY |
| US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| RU2676317C1 (ru) * | 2017-08-30 | 2018-12-27 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ pCXCRs-Fc ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО СЛИТОГО БЕЛКА, ОБЛАДАЮЩЕГО АНТИ-IL-8 АКТИВНОСТЬЮ |
| WO2023125976A1 (zh) * | 2021-12-31 | 2023-07-06 | 广州国家实验室 | 融合蛋白疫苗 |
| CN116059388A (zh) * | 2022-07-25 | 2023-05-05 | 国家纳米科学中心 | 一种多肽-化疗药物偶联物、其制备方法和应用 |
| CN117003890B (zh) * | 2023-08-09 | 2024-06-04 | 成都新诺明生物科技有限公司 | 一种含有P2和两个Fc的gE融合蛋白及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0906954A1 (en) | 1997-09-29 | 1999-04-07 | Applied Research Systems ARS Holding N.V. | Amino-terminal truncated c-c chemokines as chemokine antagonist |
| CA2245224A1 (en) * | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
| US7166694B2 (en) | 2000-04-13 | 2007-01-23 | Christoph Zielinski | Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells |
| AU2001259432B2 (en) * | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
| US7465790B2 (en) * | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| WO2009022215A1 (en) * | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
-
2011
- 2011-03-11 JP JP2012557275A patent/JP5975886B2/ja active Active
- 2011-03-11 EP EP11754148.2A patent/EP2545174B1/en active Active
- 2011-03-11 CN CN201180013504.1A patent/CN102884194B/zh active Active
- 2011-03-11 WO PCT/US2011/028070 patent/WO2011112915A2/en not_active Ceased
- 2011-03-11 US US13/577,990 patent/US9296803B2/en active Active